UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 15, 2024
MEREO BIOPHARMA GROUP PLC
(Exact name of registrant as specified in its charter)
England and Wales | 001-38452 | Not Applicable | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
4th Floor, One Cavendish Place,
London, W1G 0QF
United Kingdom
(Address of principal executive offices, including zip code)
+44-333-023-7300
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading |
Name of each exchange |
||
American Depositary Shares, each representing five Ordinary Shares, par value £0.003 per share | MREO | The Nasdaq Stock Market LLC | ||
Ordinary Shares, nominal value £0.003 per share* | * | The Nasdaq Stock Market LLC |
* | Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC. |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
Item 1.01. | Entry Into a Material Definitive Agreement. |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒ On April 15, 2024, Mereo BioPharma Group plc (the “Company”) entered into an extension letter, effective as of April 15, 2024 (the “Extension Letter”) to the cooperation agreement, dated October 28, 2022 (the “Cooperation Agreement”), between the Company and Rubric Capital Management L.P. (“Rubric Capital”). The Extension Letter waived the requirement under Section 1(f) of the Cooperation Agreement for Mr. Justin Roberts to offer to resign from the Company’s Board of Directors and all applicable committees thereof upon the termination date of the Cooperation Agreement which was immediately following the conclusion of the Company’s 2024 annual shareholder meeting (the “Termination Date”) and extended the Termination Date of the Cooperation Agreement until immediately following the conclusion of the Company’s 2025 annual shareholder meeting.
The foregoing description of the Extension Letter does not purport to be complete and is qualified in its entirety by reference to the full text of the Extension Letter, a copy of which is attached hereto as Exhibit 10.1 and is incorporated herein in its entirety by reference.
Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
Exhibit |
Description of Exhibit |
|
10.1 | Extension Letter to the Cooperation Agreement between the Company and Rubric Capital, dated April 15, 2024. | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
MEREO BIOPHARMA GROUP PLC | ||||||
Date: April 15, 2024 | By: | /s/ Charles Sermon |
||||
Name: | Charles Sermon | |||||
Title: | General Counsel |
Exhibit 10.1
Rubric Capital Management L.P.
155 East 44th St, Suite 1630
New York, NY 10017
15 April 2024
Re: Waiver of Section 1(f) of the Cooperation Agreement, dated October 28, 2022, between Mereo BioPharma Group plc (the “Company”) and Rubric Capital Management L.P. (“Rubric Capital”) (such agreement, the “Cooperation Agreement”) and Extension of the Termination Date.
To whom it may concern:
In recognition of the valuable contributions made by Justin Roberts to the Board of Directors (the “Board”) of the Company, the Board believes it would be in the best interests of the Company’s shareholders for Mr. Roberts to continue serving as a director of the Company, and for the Company to extend the date of the Termination Date.
Accordingly, the Company and Rubric Capital hereby irrevocably (i) waive the requirement under Section 1(f) of the Cooperation Agreement for Mr. Roberts to offer to resign from the Board and all applicable committees thereof upon the Termination Date, and (ii) extend the Termination Date until immediately following the end of the 2025 annual meeting of the Company’s shareholders.
Except as specifically amended herein, the Cooperation Agreement shall remain in full force and effect according to its terms. Section 20 (Governing Law and Jurisdiction) of the Cooperation Agreement shall apply in respect of this letter, amended as the context requires.
Capitalized terms used herein but not defined shall have the meanings ascribed to such terms in the Cooperation Agreement.
[Signature page follows below]
Mereo BioPharma Group plc
4th Floor, 1 Cavendish Place
London, W1G 0QF
T: +44 333 023 7300
www.mereobiopharma.com
Mereo BioPharma Group plc is company registered in England and Wales under number 9481161 whose registered office is at 4th Floor, 1 Cavendish Place, W1G 0QF.
Sincerely, | ||
MEREO BIOPHARMA GROUP PLC | ||
By: | /s/ Denise Scots-Knight | |
Name: Denise Scots-Knight |
||
Title: Chief Executive Officer |
Acknowledged and Agreed: |
||
RUBRIC CAPITAL MANAGEMENT L.P. as Manager or Sub-Manager of its funds and accounts |
||
By: Rubric Capital Management GP LLC, its General Partner |
By: | /s/ David Rosen | |
Name: David Rosen |
||
Title: Managing Member |
Mereo BioPharma Group plc
4th Floor, 1 Cavendish Place
London, W1G 0QF
T: +44 333 023 7300
www.mereobiopharma.com
Mereo BioPharma Group plc is company registered in England and Wales under number 9481161 whose registered office is at 4th Floor, 1 Cavendish Place, W1G 0QF.